Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment

被引:16
|
作者
Zhou, Hong [1 ,2 ,3 ]
Ma, Yipeng [2 ,3 ]
Liu, Fenglan [2 ,3 ]
Li, Bin [2 ,3 ]
Qiao, Dongjuan [2 ,3 ]
Ren, Peigen [1 ]
Wang, Mingjun [2 ,3 ]
机构
[1] Chinese Acad Sci, Ctr Energy Metab & Reprod, Shenzhen Inst Adv Technol, Shenzhen, Peoples R China
[2] Shenzhen Innovat Immunotechnol Co Ltd, Dept Res & Dev, Shenzhen, Peoples R China
[3] Shenzhen Inst Innovat & Translat Med, Dept Res & Dev, Shenzhen, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
CTA; NY-ESO-1; cancer vaccine; immunotherapy; solid cancer; T-CELL RESPONSES; NY-ESO-1-SPECIFIC IMMUNE-RESPONSES; TESTIS ANTIGEN NY-ESO-1; MESSENGER-RNA; OVARIAN-CANCER; POLY-ICLC; EXPRESSING NY-ESO-1; MELANOMA PATIENTS; DENDRITIC CELLS; VACCINATION;
D O I
10.3389/fimmu.2023.1255799
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
New York-esophageal cancer 1 (NY-ESO-1) belongs to the cancer testis antigen (CTA) family, and has been identified as one of the most immunogenic tumor-associated antigens (TAAs) among the family members. Given its ability to trigger spontaneous humoral and cellular immune response and restricted expression, NY-ESO-1 has emerged as one of the most promising targets for cancer immunotherapy. Cancer vaccines, an important element of cancer immunotherapy, function by presenting an exogenous source of TAA proteins, peptides, and antigenic epitopes to CD4+ T cells via major histocompatibility complex class II (MHC-II) and to CD8+ T cells via major histocompatibility complex class I (MHC-I). These mechanisms further enhance the immune response against TAAs mediated by cytotoxic T lymphocytes (CTLs) and helper T cells. NY-ESO-1-based cancer vaccines have a history of nearly two decades, starting from the first clinical trial conducted in 2003. The current cancer vaccines targeting NY-ESO-1 have various types, including Dendritic cells (DC)-based vaccines, peptide vaccines, protein vaccines, viral vaccines, bacterial vaccines, therapeutic whole-tumor cell vaccines, DNA vaccines and mRNA vaccines, which exhibit their respective benefits and obstacles in the development and application. Here, we summarized the current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment, aiming to provide perspectives for future research.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
    Thomas, Remy
    Al-Khadairi, Ghaneya
    Roelands, Jessica
    Hendrickx, Wouter
    Dermime, Said
    Bedognetti, Davide
    Decock, Julie
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [2] Protein and DNA-based vaccines with the NY-ESO-1 antigen in cancer patients
    Sharma, P
    Bajorin, DF
    Altorki, NK
    Nishikawa, H
    Old, LJ
    Gnjatic, S
    JOURNAL OF IMMUNOTHERAPY, 2005, 28 (06) : 659 - 659
  • [3] Expression and immunogenicity of NY-ESO-1 in colorectal cancer
    Li, Ya
    Song, Ruifeng
    Li, Xinqiang
    Xu, Feng
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2017, 13 (06) : 3581 - 3585
  • [4] NY-ESO-1 and clinicopathological features in ovarian cancer
    Topka, Charlotte R.
    ElMasri, Wafic M.
    Magyar, Clara E.
    Song, Min
    Dorigo, Oliver
    CANCER RESEARCH, 2012, 72
  • [5] The role of the NY-ESO-1 in the prognosis of gastric cancer
    Misir, Zvonimir
    Glavcic, Goran
    Jankovic, Suzana
    Kruljac, Ivan
    Cugura-Filipovic, Jaksa
    Cimiimic, Kristina
    Ulamec, Monika
    BIOMOLECULES AND BIOMEDICINE, 2024, 24 (04): : 813 - 820
  • [6] NY-ESO-1 expression and immunogenicity in esophageal cancer
    Fujita, S
    Wada, H
    Jungbluth, AA
    Sato, S
    Nakata, T
    Noguchi, Y
    Doki, Y
    Yasui, M
    Sugita, Y
    Yasuda, T
    Yano, M
    Ono, T
    Chen, YT
    Higashiyama, M
    Gnjatic, S
    Old, LJ
    Nakayama, E
    Monden, M
    CLINICAL CANCER RESEARCH, 2004, 10 (19) : 6551 - 6558
  • [7] ADOPTIVE TRANSFER IMMUNOTHERAPY TARGETING NY-ESO-1 FOR TREATMENT OF GLIOBLASTOMA
    Everson, Richard G.
    Lisiero, Dominique N.
    Soto, Horacio
    Liau, Linda M.
    Prins, Robert M.
    NEURO-ONCOLOGY, 2012, 14 : 41 - 42
  • [8] Public NY-ESO-1 specific TCRs as novel biomarkers for immune monitoring of NY-ESO-1 positive cancer patients
    Lu, Hailing
    Pollack, Seth
    Somaiah, Neeta
    Chawla, Sant
    Hwu, Patrick
    Vignali, Marissa
    Rytlewski, Julie
    Gnjatic, Sacha
    ter Meulen, Jan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [9] NY-ESO-1 is associated with an aggressive phenotype of ovarian cancer
    Szender, J. B.
    Papanicolau-Sengos, A.
    Eng, K.
    Miliotto, A. J.
    Lugade, A.
    Gnjatic, S.
    Matsuzaki, J.
    Odunsi, K.
    GYNECOLOGIC ONCOLOGY, 2017, 145 : 30 - 30
  • [10] NY-ESO-1 antigen: A promising frontier in cancer immunotherapy
    Alsalloum, Alaa
    Shevchenko, Julia A.
    Sennikov, Sergey
    CLINICAL AND TRANSLATIONAL MEDICINE, 2024, 14 (09):